Immutep Limited (ASX: IMM) - ETF Exposure

Current share price for IMM : $0.051 0.001 (2%)⁺

Immutep Ltd (IMM) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Phase III, clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG 3) related immunotherapies for cancer and autoimmune disease.

IMM General Information ⁺

ASX Code	IMM
Website	http://www.immutep.com
Industry/Sector	Biotechnology
Market Cap ($M)	75
IMM Share Price	$0.051
Day High	$0.051
Day Low	$0.048
Last Close	$0.050
IMM Share Price Movement	$0.00 ( 2% )

Prices as at 16:40, 12 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to IMM

Immutep Limited (IMM) is held across 8 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when IMM moves, funds like IMPQ, SSO, ISO and VAS that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 0.5% to IMM , while the average exposure across all 8 ETFs that hold it is around 0.1% .

Top ETF holdings

eInvest Better Future (Managed Fund) (IMPQ) ~ 0.5%
SPDR S&P/ASX Small Ordinaries Fund (SSO) ~ 0%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0%
Vanguard Australian Shares Index ETF (VAS) ~ 0%

Last updated: ETF data and holdings as at 12 August 2026

Own IMM directly or through an ETF?

How does holding Immutep Limited (IMM) shares directly compare to ETFs that include it?

	IMM Direct	IMPQ ASX	SSO ASX	ISO ASX	VAS ASX
Holdings	1 company	41 holdings	201 holdings	198 holdings	301 holdings
IMM Weight	100%	0.5%	0%	0%	0%
Diversification	Single Stock	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	0.89% p.a.	0.5% p.a.	0.55% p.a.	0.07% p.a.
Approx. Yield	-	2.03%	8.83%	4.15%	2.85%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not IMM's direct yield. Annual cost uses each ETF's MER.

IMM Exposure on $10,000 investment

How a $10,000 investment in Immutep Limited (IMM) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Immutep Limited (IMM)	Direct share	$0.051	8.51%	+$851	$10,851
eInvest Better Future (Managed Fund) (IMPQ)	Equity - Australia Small/Mid Cap	$4.430	2.31%	+$231	$10,231
SPDR S&P/ASX Small Ordinaries Fund (SSO)	Equity - Australia Small/Mid Cap	$15.190	4.98%	+$498	$10,498
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$5.270	4.77%	+$477	$10,477
Vanguard Australian Shares Index ETF (VAS)	Equity - Australia	$114.070	0.79%	+$79	$10,079

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Immutep Limited (IMM) ETFs

8 ETFs hold Immutep Limited (IMM).

ETF	IMM Weight	MER	Yield
eInvest Better Future (Managed Fund) (IMPQ)	0.5%	0.89%	2.03%
SPDR S&P/ASX Small Ordinaries Fund (SSO)	0%	0.5%	8.83%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0%	0.55%	4.15%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	2.85%

View all 8 ETFs

Immutep Limited (IMM) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Immutep Limited (IMM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immutep Limited (IMM) price-sensitive announcements

IMM - Immutep Quarterly Activities Report and Appendix 4C

Immutep Limited, a biotechnology company developing novel immunotherapies for cancer and a

Immutep Limited (IMM)
30 Jul 2026 | 8:24 AM

IMM - TACTI-004 Update & Positive Mature Data from INSIGHT-003

Immutep Limited announced significant advancements in their clinical trials for 1st line n

Immutep Limited (IMM)
13 Jul 2026 | 9:38 AM

IMM - Immutep Quarterly Activities Report and Appendix 4C

Immutep Limited reported its quarterly activities for the period ending 31 March 2026. The

Immutep Limited (IMM)
30 Apr 2026 | 9:01 AM

IMM - Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma

Immutep Limited has announced that the FDA has granted Orphan Drug Designation (ODD) for e

Immutep Limited (IMM)
15 Apr 2026 | 9:27 AM

Immutep Limited (IMM) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	Immutep Quarterly Activities Report and Appendix 4C	30 Jul 2026 8:24AM	$0.047	$0.051	risen by 8.51%
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	Abstract Accepted for Presentation at ESMO Congress 2026	24 Jul 2026 9:01AM	$0.050	$0.051	risen by 2%
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	Fourth U.S. Patent Secured for Efti and PD-1 Combination	14 Jul 2026 12:11PM	$0.055	$0.051	fallen by 7.27%
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	TACTI-004 Update & Positive Mature Data from INSIGHT-003	13 Jul 2026 9:38AM	$0.051	$0.051	fallen by 0%
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	Ceasing to be a substantial holder	1 Jul 2026 8:14AM	$0.053	$0.051	fallen by 3.77%
Immutep Limited (IMM) ORDINARY FULLY PAID	Health Care	$75	Becoming a substantial holder	17 Jun 2026 8:22AM	$0.046	$0.051	risen by 10.87%

IMM Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$2.90	-37.60%	0.00%	0.0%
2026F	C2	-$4.60	8.30%	0.00%	0.0%
2025A	-$61.43	-$4.20	18.50%	0.00%	0.0%

IMM Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
CSL Limited (CSL)	$66,248M	0.1108	-0.1236	0.0167	14.8332	16.9242	16.6464	3.22%	2.62%	2.73%
Clinuvel Pharmaceuticals Limited (CUV)	$490M	0.0287	0.0000	0.0000	13.5237	0.0000	0.0000	0.51%	0.00%	0.00%
Immutep Limited (IMM)	$74M	0.1854	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,130M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,759M	-1.3893	0.0000	-0.1450	0.0000	279.2422	326.5896	0.00%	0.00%	0.00%

IMM Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	0.52	0.00
Market	0.31	13.10	1.15	0.66
Sector	0.52	33.10	2.46	2.71

IMM Directors

Name	Position	Start Date
Mr Marc Voigt	Chief Financial Officer, Chief Executive Officer, Executive Director	9 Jul 2014
Professor Frederic Triebel	Executive Director	13 Sep 2022
Dr Russell J Howard	Non-Executive Chairman, Non-Executive Director	8 May 2013
Mr Pete A Meyers	Non-Executive Deputy Chairman, Non-Executive Director	12 Feb 2014
Ms Lis (Elisabeth) Boyce	Non-Executive Director	11 Apr 2023

Immutep Limited (IMM) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
18 Sep 2024	VOIGT, Marc	Buy	Indirect Shares	29,500	$0.340	$10,030.000
16 Mar 2020	CHAMBERLAIN, Grant	Buy	Indirect Shares	360,623	$0.277	$99,755.740
6 Aug 2019	CHAMBERLAIN, Grant	Issued	Indirect Shares	401,635	$0.021	$8,434.335

See all changes in directors' interest & trades for Immutep Limited (IMM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMM Management

Name	Position
Christian Mueller	Chief Development Officer
Florian Vogl	Chief Medical Officer
Deanne Miller	Chief Operating Officer,Company Secretary,General Counsel

IMM Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immutep Limited (IMM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
210,913,979 (14.50%)	The Bank of New York Mellon Corporation
203,196,083 (13.91%)	Regal Funds Management Pty Ltd
147,623,939 (10.16%)	Insignia Financial Ltd

IMM Calendar of Events

Date	Event
24 February 2027	Report (Interim)
26 October 2026	Report (Annual)
23 October 2026	Report (Annual)
28 August 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us